Clinical efficacy of tandospirone augmentation in patients with major depressive disorder

A randomized controlled trial

Kazuo Yamada, Gohei Yagi, Shigenobu Kanba

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The purpose of the present paper was to investigate the efficacy of augmentation of clomipramine (CMI) by tandospirone in 36 untreated outpatients with major depressive disorder. Twelve patients were treated with CMI and tandospirone (T group), 12 with CMI and diazepam (D group) and 12 with CMI alone (C group) for 6 weeks. No statistically significant differences in the percentage improvement of the Hamilton Depression Rating Scale (17 items; HDRS-17) and the Hamilton Anxiety Rating Scale (14 items; HARS-14) scores were shown among the three treatment groups. However, at 2 weeks, the percentage improvement of HDRS-17 score in the T group tended to be higher than that in the D and C groups, although there was no statistically significant difference among the three treatment groups. No change in plasma prolactin level or adverse events was induced by the addition of tandospirone. These results suggest that 6 weeks of treatment with tandospirone or diazepam was not effective for augmentation of CMI in major depressive disorder patients. However, augmentation of antidepressants by tandospirone administration for a few weeks might induce early expression of antidepressive effects.

Original languageEnglish
Pages (from-to)183-187
Number of pages5
JournalPsychiatry and clinical neurosciences
Volume57
Issue number2
DOIs
Publication statusPublished - Apr 1 2003

Fingerprint

Clomipramine
Major Depressive Disorder
Randomized Controlled Trials
Diazepam
Dilatation and Curettage
Prolactin
Antidepressive Agents
Outpatients
Therapeutics
Anxiety
tandospirone
Depression

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Clinical efficacy of tandospirone augmentation in patients with major depressive disorder : A randomized controlled trial. / Yamada, Kazuo; Yagi, Gohei; Kanba, Shigenobu.

In: Psychiatry and clinical neurosciences, Vol. 57, No. 2, 01.04.2003, p. 183-187.

Research output: Contribution to journalArticle

@article{c06d0a80c0614664b4b1f86617ff6fb5,
title = "Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: A randomized controlled trial",
abstract = "The purpose of the present paper was to investigate the efficacy of augmentation of clomipramine (CMI) by tandospirone in 36 untreated outpatients with major depressive disorder. Twelve patients were treated with CMI and tandospirone (T group), 12 with CMI and diazepam (D group) and 12 with CMI alone (C group) for 6 weeks. No statistically significant differences in the percentage improvement of the Hamilton Depression Rating Scale (17 items; HDRS-17) and the Hamilton Anxiety Rating Scale (14 items; HARS-14) scores were shown among the three treatment groups. However, at 2 weeks, the percentage improvement of HDRS-17 score in the T group tended to be higher than that in the D and C groups, although there was no statistically significant difference among the three treatment groups. No change in plasma prolactin level or adverse events was induced by the addition of tandospirone. These results suggest that 6 weeks of treatment with tandospirone or diazepam was not effective for augmentation of CMI in major depressive disorder patients. However, augmentation of antidepressants by tandospirone administration for a few weeks might induce early expression of antidepressive effects.",
author = "Kazuo Yamada and Gohei Yagi and Shigenobu Kanba",
year = "2003",
month = "4",
day = "1",
doi = "10.1046/j.1440-1819.2003.01099.x",
language = "English",
volume = "57",
pages = "183--187",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Clinical efficacy of tandospirone augmentation in patients with major depressive disorder

T2 - A randomized controlled trial

AU - Yamada, Kazuo

AU - Yagi, Gohei

AU - Kanba, Shigenobu

PY - 2003/4/1

Y1 - 2003/4/1

N2 - The purpose of the present paper was to investigate the efficacy of augmentation of clomipramine (CMI) by tandospirone in 36 untreated outpatients with major depressive disorder. Twelve patients were treated with CMI and tandospirone (T group), 12 with CMI and diazepam (D group) and 12 with CMI alone (C group) for 6 weeks. No statistically significant differences in the percentage improvement of the Hamilton Depression Rating Scale (17 items; HDRS-17) and the Hamilton Anxiety Rating Scale (14 items; HARS-14) scores were shown among the three treatment groups. However, at 2 weeks, the percentage improvement of HDRS-17 score in the T group tended to be higher than that in the D and C groups, although there was no statistically significant difference among the three treatment groups. No change in plasma prolactin level or adverse events was induced by the addition of tandospirone. These results suggest that 6 weeks of treatment with tandospirone or diazepam was not effective for augmentation of CMI in major depressive disorder patients. However, augmentation of antidepressants by tandospirone administration for a few weeks might induce early expression of antidepressive effects.

AB - The purpose of the present paper was to investigate the efficacy of augmentation of clomipramine (CMI) by tandospirone in 36 untreated outpatients with major depressive disorder. Twelve patients were treated with CMI and tandospirone (T group), 12 with CMI and diazepam (D group) and 12 with CMI alone (C group) for 6 weeks. No statistically significant differences in the percentage improvement of the Hamilton Depression Rating Scale (17 items; HDRS-17) and the Hamilton Anxiety Rating Scale (14 items; HARS-14) scores were shown among the three treatment groups. However, at 2 weeks, the percentage improvement of HDRS-17 score in the T group tended to be higher than that in the D and C groups, although there was no statistically significant difference among the three treatment groups. No change in plasma prolactin level or adverse events was induced by the addition of tandospirone. These results suggest that 6 weeks of treatment with tandospirone or diazepam was not effective for augmentation of CMI in major depressive disorder patients. However, augmentation of antidepressants by tandospirone administration for a few weeks might induce early expression of antidepressive effects.

UR - http://www.scopus.com/inward/record.url?scp=0037398516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037398516&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1819.2003.01099.x

DO - 10.1046/j.1440-1819.2003.01099.x

M3 - Article

VL - 57

SP - 183

EP - 187

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

SN - 1323-1316

IS - 2

ER -